Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J R Infante

Showing results (51-60 of 54) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 54 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 24, 2016
CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancerE G Chiorean, D D Von Hoff, M Reni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 21, 2014
Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trialA M Menzies, M T Ashworth, S Swann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 30, 2016
Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancerJ F Liu, K N Moore, M J Birrer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 23, 2018
Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumorsA Italiano, J R Infante, G I Shapiro, et al.
Pageof 6

Showing results (51-60 of 54) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 54 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 24, 2016
CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancerE G Chiorean, D D Von Hoff, M Reni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 21, 2014
Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trialA M Menzies, M T Ashworth, S Swann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 30, 2016
Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancerJ F Liu, K N Moore, M J Birrer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 23, 2018
Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumorsA Italiano, J R Infante, G I Shapiro, et al.
Pageof 6